Author: Foret, Thomas; Dufrost, Virginie; du Mont, Lucie Salomon; Costa, Patricia; Lefevre, Benjamin; Lacolley, Patrick; Regnault, Veronique; Zuily, Stephane; Wahl, Denis
Title: Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders? Cord-id: vd01nthu Document date: 2021_7_3
ID: vd01nthu
Snippet: PURPOSE OF REVIEW: COVID-19 patients have a procoagulant state with a high prevalence of thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) has been suggested by several reports. Here, we reviewed 48 studies investigating aPL in COVID-19 patients. RECENT FINDINGS: Prevalence of Lupus Anticoagulant (LA) ranged from 35% to 92% in ICU patients. Anti-cardiolipin (aCL) IgG and IgM were found in up to 52% and up to 40% of patients respectively. Anti-β(2)-glycopro
Document: PURPOSE OF REVIEW: COVID-19 patients have a procoagulant state with a high prevalence of thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) has been suggested by several reports. Here, we reviewed 48 studies investigating aPL in COVID-19 patients. RECENT FINDINGS: Prevalence of Lupus Anticoagulant (LA) ranged from 35% to 92% in ICU patients. Anti-cardiolipin (aCL) IgG and IgM were found in up to 52% and up to 40% of patients respectively. Anti-β(2)-glycoprotein I (aβ(2)-GPI) IgG and IgM were found in up to 39% and up to 34% of patients respectively. Between 1% and 12% of patients had a triple positive aPL profile. There was a high prevalence of aβ(2)-GPI and aCL IgA isotype. Two cohort studies found few persistent LA but more persistent solid phase assay aPL over time. SUMMARY: aPL determination and their potential role is a real challenge for the treatment of this disease.
Search related documents:
Co phrase search for related documents- absence presence and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and low prevalence: 1, 2, 3, 4
- absence presence and lupus erythematosus: 1
- acl anticardiolipin and acute phase: 1
- acl anticardiolipin and acute respiratory: 1, 2
- acl anticardiolipin and lupus anticoagulant: 1, 2, 3, 4, 5, 6, 7
- acl positive and acute phase: 1
- acl positive and lupus anticoagulant: 1, 2, 3
- acl prevalence and lupus anticoagulant: 1, 2
Co phrase search for related documents, hyperlinks ordered by date